These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35933456)

  • 1. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth.
    Liu X; Chipurupalli S; Jiang P; Tavasoli M; Yoo BH; McPhee M; Mazinani S; Francia G; Kerbel RS; Rosen KV
    Cell Death Dis; 2022 Aug; 13(8):687. PubMed ID: 35933456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.
    Khan IA; Yoo BH; McPhee M; Masson O; Surette A; Dakin-Hache K; Younis T; Bethune G; Rosen KV
    Breast Cancer Res; 2018 Dec; 20(1):151. PubMed ID: 30545388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.
    Khan IA; Yoo BH; Masson O; Baron S; Corkery D; Dellaire G; Attardi LD; Rosen KV
    Oncogene; 2016 Nov; 35(44):5759-5769. PubMed ID: 27109096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
    Surette A; Yoo BH; Younis T; Matheson K; Rameh T; Snowdon J; Bethune G; Rosen KV
    Breast Cancer Res Treat; 2021 Jun; 187(3):743-758. PubMed ID: 33728523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment.
    Rayavarapu RR; Heiden B; Pagani N; Shaw MM; Shuff S; Zhang S; Schafer ZT
    J Biol Chem; 2015 Apr; 290(14):8722-33. PubMed ID: 25681438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Drucker A; Yoo BH; Khan IA; Choi D; Montermini L; Liu X; Jovanovic S; Younis T; Rosen KV
    Breast Cancer Res; 2020 Oct; 22(1):105. PubMed ID: 33023655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells.
    Haenssen KK; Caldwell SA; Shahriari KS; Jackson SR; Whelan KA; Klein-Szanto AJ; Reginato MJ
    J Cell Sci; 2010 Apr; 123(Pt 8):1373-82. PubMed ID: 20332114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
    Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
    Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance.
    Whelan KA; Schwab LP; Karakashev SV; Franchetti L; Johannes GJ; Seagroves TN; Reginato MJ
    J Biol Chem; 2013 May; 288(22):15865-77. PubMed ID: 23585570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
    Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
    Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
    Anastasi S; Sala G; Huiping C; Caprini E; Russo G; Iacovelli S; Lucini F; Ingvarsson S; Segatto O
    Oncogene; 2005 Jun; 24(28):4540-8. PubMed ID: 15856022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix.
    Khan IA; Yoo BH; Rak J; Rosen KV
    Oncotarget; 2017 Dec; 8(62):105383-105396. PubMed ID: 29285258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.